Angiotensin II and sympathetic activity in sodium-restricted essential hypertension
- PMID: 7721403
- DOI: 10.1161/01.hyp.25.4.595
Angiotensin II and sympathetic activity in sodium-restricted essential hypertension
Abstract
Angiotensin II (Ang II) potentiates sympathetic neurotransmission by presynaptic facilitation of norepinephrine release. We investigated whether endogenous Ang II modulates peripheral sympathetic activity in sodium-depleted essential hypertensive patients. We evaluated the effect of intrabrachial infusion of saralasin, an Ang II antagonist (5 micrograms/100 mL forearm tissue per minute), and benazeprilat, an angiotensin-converting enzyme inhibitor (2 micrograms/100 mL forearm tissue per minute), on forearm vasoconstriction (measured by strain-gauge venous plethysmography) induced by the application of lower body negative pressure (-10 mm Hg for 5 minutes). Both saralasin and benazeprilat (n = 6 for each group) blunted the vasoconstrictor action of lower body negative pressure, suggesting that circulating Ang II modulates peripheral sympathetic activity. In addition, since beta-adrenoceptor stimulation can activate the production of vascular Ang II, the effect of saralasin and benazeprilat on lower body negative pressure application was evaluated in the presence of isoproterenol (0.09 microgram/100 mL forearm tissue per minute) and propranolol (10 micrograms/100 mL forearm tissue per minute). In two other groups of hypertensive patients, isoproterenol infusion increased the release of Ang II in the forearm vasculature (arteriovenous values measured by radioimmunoassay). Furthermore, isoproterenol potentiated lower body negative pressure-induced vasoconstriction. This facilitating effect was abolished by either saralasin or benazeprilat (n = 6 for each group). In contrast, in two further groups of patients (n = 6 for each group), in the presence of the beta-blocker propranolol saralasin and benazeprilat did not alter the vasoconstrictor action of the endogenous sympathetic stimulus.(ABSTRACT TRUNCATED AT 250 WORDS)
Similar articles
-
Vascular renin-angiotensin system and neurotransmission in hypertensive persons.Hypertension. 1991 Sep;18(3):266-77. doi: 10.1161/01.hyp.18.3.266. Hypertension. 1991. PMID: 1653766
-
Persistence of sympathetic-mediated forearm vasoconstriction after alpha-blockade in hypertensive patients.Circulation. 1989 Sep;80(3):485-90. doi: 10.1161/01.cir.80.3.485. Circulation. 1989. PMID: 2569947
-
Influence of angiotensin II, alpha- and beta-adrenoceptors on peripheral noradrenergic neurotransmission in canine gracilis muscle in vivo.Acta Physiol Scand. 1992 Aug;145(4):333-43. doi: 10.1111/j.1748-1716.1992.tb09373.x. Acta Physiol Scand. 1992. PMID: 1326853
-
Interaction between the renin-angiotensin-aldosterone and sympathetic nervous systems.J Cardiovasc Pharmacol. 1992;19 Suppl 6:S80-8. doi: 10.1097/00005344-199219006-00013. J Cardiovasc Pharmacol. 1992. PMID: 1382170 Review.
-
The renin-angiotensin-aldosterone system: a specific target for hypertension management.Am J Hypertens. 1999 Dec;12(12 Pt 3):205S-213S. doi: 10.1016/s0895-7061(99)00103-x. Am J Hypertens. 1999. PMID: 10619573 Review.
Cited by
-
Sympathetic regulation of vascular function in health and disease.Front Physiol. 2012 Jul 24;3:284. doi: 10.3389/fphys.2012.00284. eCollection 2012. Front Physiol. 2012. PMID: 22934037 Free PMC article.
-
Regulation of peripheral vascular tone in patients with heart failure: contribution of angiotensin II.Heart. 1998 Aug;80(2):134-40. doi: 10.1136/hrt.80.2.134. Heart. 1998. PMID: 9813557 Free PMC article. Clinical Trial.
-
Association of Obesity, Sarcopenia, and Sarcopenic Obesity With Hypertension in Adults: A Cross-Sectional Study From Ravansar, Iran During 2014-2017.Front Public Health. 2022 Feb 2;9:705055. doi: 10.3389/fpubh.2021.705055. eCollection 2021. Front Public Health. 2022. PMID: 35186858 Free PMC article.
-
Obesity and hypertension.Exp Ther Med. 2016 Oct;12(4):2395-2399. doi: 10.3892/etm.2016.3667. Epub 2016 Sep 6. Exp Ther Med. 2016. PMID: 27703502 Free PMC article.
-
Cardiovascular Risk in Patients with Prehypertension and the Metabolic Syndrome.Curr Hypertens Rep. 2018 Mar 6;20(2):15. doi: 10.1007/s11906-018-0801-2. Curr Hypertens Rep. 2018. PMID: 29511907 Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous